Matt Kalaycio

All Specialties

CME Events
REGISTER or LOGIN

/

ADVERTISEMENT

Matt Kalaycio

Article

Other therapy options may relegate omacetaxine to last-line choice for chronic or accelerated phase CML

Author:: Matt Kalaycio

Publish date: July 6, 2013

Read More

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

MDEdge

About Us

Facebook
Linkedin
Twitter

Editorial Policy

Medscape Customer Support

Frequently Asked Questions

Advertise with MDedge

See more with MDedge! See our Other Publications

Copyright © 2026 Frontline Medical Communications Inc. , Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer .